Laboratorios Farmaceuticos Rovi SA 2020 SR
The report highlights ROVI's 2020 performance, noting a 10% growth in operating revenue and a 55% increase in net profit despite the COVID-19 pandemic. A major milestone was the collaboration with Moderna for the fill-finish manufacture of its COVID-19 vaccine. The company achieved an excellent ESG rating from Sustainalytics, ranking second among 360 pharmaceutical companies. ROVI also implemented a new Climate Change Policy and committed to 100% renewable electricity at its industrial plants. Social initiatives included donating one million masks and supporting various employment programs for people with disabilities.
Company: Laboratorios Farmaceuticos Rovi SA
Sector: Manufacturing
Country: Spain
Year: 2020
Type: SR
Pages: 98
Back to company
Laboratorios Farmaceuticos Rovi SA
Corporate Social Responsibility Report
The report highlights ROVI's 2020 performance, noting a 10% growth in operating revenue and a 55% increase in net profit despite the COVID-19 pandemic. A major milestone was the collaboration with Moderna for the fill-finish manufacture of its COVID-19 vaccine. The company achieved an excellent ESG rating from Sustainalytics, ranking second among 360 pharmaceutical companies. ROVI also implemented a new Climate Change Policy and committed to 100% renewable electricity at its industrial plants. Social initiatives included donating one million masks and supporting various employment programs for people with disabilities.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2020
Reporting Period
Jan 1, 2020 - Dec 31, 2020
Fiscal Year
2020
Type
Sustainability Report
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
Sustainable Development Goals
Other Standards
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Emissions
Scope 1:
Scope 2:
Energy Consumption
Water Consumption
Total Waste
Employees